Does RALTEGRAVIR Cause Malignant neoplasm progression? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Malignant neoplasm progression have been filed in association with RALTEGRAVIR (ISENTRESS). This represents 0.1% of all adverse event reports for RALTEGRAVIR.
5
Reports of Malignant neoplasm progression with RALTEGRAVIR
0.1%
of all RALTEGRAVIR reports
1
Deaths
3
Hospitalizations
How Dangerous Is Malignant neoplasm progression From RALTEGRAVIR?
Of the 5 reports, 1 (20.0%) resulted in death, 3 (60.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RALTEGRAVIR. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does RALTEGRAVIR Cause?
Foetal exposure during pregnancy (1,033)
Maternal exposure during pregnancy (726)
Exposure during pregnancy (700)
Drug interaction (552)
Virologic failure (517)
Depression (482)
Death (431)
Pathogen resistance (425)
Drug resistance (388)
No adverse event (339)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which RALTEGRAVIR Alternatives Have Lower Malignant neoplasm progression Risk?
RALTEGRAVIR vs RALTITREXED
RALTEGRAVIR vs RAMELTEON
RALTEGRAVIR vs RAMIPRIL
RALTEGRAVIR vs RAMUCIRUMAB
RALTEGRAVIR vs RANEXA